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Background
Cisplatin is a potent chemotherapeutic used to treat a multitude of solid cancers,
including lung, testicular, bladder, cervical, and ovarian (1). Despite its effective
chemotherapeutic properties, cisplatin has serious side effects including bone marrow
suppression, ototoxicity, anaphylaxis, and nephrotoxicity. Of these, concern for developing
cisplatin-induced nephrotoxicity leading to acute kidney injury (AKI) is high. After a single dose
of cisplatin, 33% of patients will develop nephrotoxicity (2). Acute kidney injury is defined as
the rapid loss of renal function, and the mortality rate for all forms of AKI ranges from 20-80%,
with the highest mortality in ICU patients (3). Furthermore, cisplatin-induced AKI accounts for
19% of all cases of AKI, and thus puts a significant percentage of patients at risk for increased
mortality (3).
Within the human body, cisplatin causes cross-linking of DNA strands, thereby inhibiting
DNA replication and gene transcription (4). As a result, cancer cells can be destroyed and the
cancer spreads at a slower rate or is even halted (3). However, the effect of cisplatin is damaging
within the kidney, as cisplatin substantially accumulates in the proximal tubule cells and
interferes with processes that lead to severe proximal tubule cell death, ultimately resulting in
kidney injury and the subsequent loss of function (5). Proximal tubular injury is just one of the
four major mechanisms of the pathophysiology of cisplatin-induced AKI, alongside
inflammation, oxidative stress, and vascular injury in the kidney (6).
Upon cisplatin (CDDP) administration, there is a robust pro-inflammatory response, and
levels of Tnf, Il6, Cxcl1, and Mcp-1 are increased. Tnfα is a mediator of inflammatory tissue
damage, Il6 promotes maintenance of a chronic inflammatory state, Cxcl1 recruits neutrophils to
sites of tissue inflammation, and Mcp-1 plays a role in macrophage recruitment and activation.
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More specifically, cisplatin increases serum and urine concentrations of Tnfα. Recent studies on
Tnfα -1-mice have revealed that local production of Tnfα by resident kidney cells rather than by
bone marrow-derived infiltrating immune cells may be key in cisplatin-induced AKI. However,
inflammatory cells of the immune system (T cells, macrophages, neutrophils, and mast cells) that
infiltrate the kidney tissue still play a role in the development of cisplatin-induced AKI (6).
In addition to high levels of proximal tubule damaging leading to a rapid decline in
kidney function and AKI, recent studies have indicated that patients with cisplatin-induced AKI
are ten times more likely to develop chronic kidney disease (CKD). CKD is marked by chronic
inflammation, the development of fibrosis, and a gradual decline in kidney function. Patients
with severe CKD often require dialysis, which is costly and does not always improve kidney
function. In addition, CKD is also associated with an increased mortality rate (3).
Ideally, physicians would want to treat cancer patients with a therapeutic agent to curtail
Table 1: General measures for prevention and treatment of
cisplatin-induced AKI.
(1) Determine renal function (GFR) before each session of
cisplatin treatment
(2) Determine the risk of AKI (high risk; females, elderly patients,
dehydration, patients with CKD and repeated doses of cisplatin)

nephrotoxic

side

effects

(3) Adjust cisplatin dose according to patient's renal function
(4) Start hydration (with saline) before cisplatin and maintain for
at least 3 days after treatment
(5) Watch for electrolyte wasting (e.g., Mg), replace appropriately
(6) Avoid concomitant nephrotoxic agents (NSAIDs,
aminoglycosides, contrast agents, etc.)
(7) Determine renal function within 1 week of treatment
(8) Amifostine may be considered in patients with high risk of
AKI
(9) Consider newer, less nephrotoxic platinums such as
carboplatin and oxaliplatin
GFR: glomerular filtration rate, AKI: acute kidney injury, CKD:
chronic kidney injury, Mg: magnesium, and NSAIDs: nonsteroid
anti-inflammatory drugs.
Source: Astolfi, Laura et al (7)

oncologists to increase dose

associated with cisplatin. In
doing so, this would enable

of CDDP given to improve
efficacy of the treatment.
Unfortunately, there are no
clinically available agents,
but only general measures for
prevention and treatment of
cisplatin-induced

AKI,

as
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shown in Table 1 (7). Furthermore, potential therapeutics usually fail in early clinical trials (5).
The reason for this is two-fold. For one, design of clinical trials for testing renoprotective/
injury-ameliorating agents is poor. There are few biomarkers that can be used to determine
improvement in renal injury, and often patients who are enrolled in studies have pre-existing
conditions like diabetes or cardiovascular disease, that may already alter renal outcomes (5).
Secondly, most experimentally designed therapeutics are tested in mouse models in such a way
that may not be physiologically relevant to humans. In the Siskind lab, we believe the key to
finding a renoprotective therapy is to change the mouse model of CDDP AKI.
The significance of the work proposed here is that 1.) we have developed a model of
cisplatin dosing that better recapitulates the dosing regimen humans receive and may lead to
more physiologically relevant outcomes, and 2.) this model can be used to determine long-term
effects of cisplatin-induced kidney injury. This clinically relevant mouse model will reveal new
insight to the differential effects of cisplatin, and over time, giving us the ability to identify novel
therapeutic targets.

Significance
Previously, the mouse model used for cisplatin-induced AKI consisted of injecting mice
with one, high dose of cisplatin (20-25 mg/kg) that causes mice to die 3-4 days after treatment
due to a high level of kidney injury and rapid loss of kidney function, as seen by Schematic 1.
However, this model does not recapitulate the dosing regimen patients receive, which consists of
administration of low doses of cisplatin over an extended period of time to curtail nephrotoxicity
while maintaining therapeutic efficacy. In addition, this model does not allow for long-term
studies of renal outcomes that may be associated with CKD. To address these limitations, our
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laboratory has developed a repeated dosing regimen of cisplatin in which 8-week FVB/n mice
are treated with 7 mg/kg cisplatin once a week for 4 weeks and are sacrificed at Day 24, as seen
by Schematic 2. With this dosing regimen, FVB/n mice survive the 24-day dosing regimen and
develop renal fibrosis indicative of CKD (5).

Day 0
Dose 1

Schematic 1:
Standard Model
20-25 mg/kg

FVB/n mice
7 mg/kg

Schematic 2: Repeated Dosing Model
7 mg/kg
7 mg/kg
7 mg/kg

FVB/n mice

Day 21
Dose 4

Dose 3

Day 14

Dose 2

Day 7

Dose 1

Day 0

72 hrs

SAC

FVB/n mice are a widely used inbred strain, with white fur and blindness. While we used
the FVB/n mouse strain to develop our repeated dosing model, the most commonly used strain of
mouse in research, particularly kidney research, is the C57BL/6J with a phenotype of black fur.
In fact, a majority of commercially available genetically manipulated mouse models are on the
C57BL/6J background. The ultimate goal of developing our clinically relevant cisplatin repeated
dosing regimen is to identify and test novel, therapeutic targets for the treatment of kidney
injury, of which being able to use genetically manipulated mouse models would be beneficial.
Thus, being able to utilize our repeated dosing regimen in C57BL/6J mice would be ideal.

FVB/n
mice

C57BL/6J mice
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Unfortunately, this strain has been shown to be resistant to renal fibrosis in some models
of experimental fibrosis, including BSA-induced fibrosis and unilateral ureteral obstruction.
Although it has not been reported whether or not C57BL/6J mice are resistant to developing
interstitial fibrosis (the type of fibrosis that FVB/n mice develop with repeated dosing of
cisplatin), this may be a potential drawback of incorporating our repeated dosing regimen into
C57BL/6J mice for further experiments. Table 2 outlines the susceptibility of both C57BL/6J and
FVB/n mice to different types of organ fibrosis (8).
Table 2: Various Types of Organ Fibrosis and Mouse Strain Susceptibility
C57BL/6J mice
FVB/n mice
Renal
Resistant
Susceptible
Hepatic
Resistant
Resistant
Cardiac
Resistant
Resistant
Pulmonary Susceptible
Susceptible
Intestinal
Susceptible
Susceptible

Preliminary Results
Our repeated dosing model in FVB/n mice treated with 7 mg/kg of cisplatin resulted in a
robust inflammatory response with elevated cytokine and chemokine levels, but low levels of
cell death. We saw the development of renal fibrosis as evidenced by the increase of fibrotic
markers like fibronectin, TGFβ, α-SMA IHC, and Sirius Red/Fast Green Staining. As fibrosis is
a major trait of CKD, these data demonstrate that the repeated dosing model can be used to study
AKI to CKD progression (9).
This repeated dosing model was then done in C57BL/6J mice in order to determine if the
same dose of cisplatin would also lead to the development of fibrosis in this strain. However,
when treated with 7 mg/kg cisplatin once a week for four weeks, preliminary results indicated
that there was not a significant change in inflammatory cytokine and chemokine levels (Figure
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1). Furthermore, C57BL/6J mice did not develop renal fibrosis as determined by expression
Col1a1 and Pai-1, levels of α-SMA on IHC, and Sirius Red/Fast Green Staining (Figure 2).
Col1a1 (Figure 2A), encodes for collagen type 1 protein, and Pai-1 (Figure 2B), produced by
inflammatory cells and leads to the accumulation of scar tissue in the kidney, did not show a
significant change in levels. α-SMA IHC is a stain for myofibroblasts, which produce collagen
leading to fibrosis (Figure 2C). Sirius Red/Fast Green is a stain for collagen deposition (Figure
3D). Sirius Red binds to all types of collagen, whereas fast green stains non-collagenous proteins
(10). In the FVB/n mice, there was a distinct color change between the vehicle and cisplatin
treated kidney section. Conversely, in the C57BL/6J mice, there is a lack of change in colors
between the vehicle and cisplatin kidney sections. This raised the question of whether C57BL/6J
mice are resistant to developing interstitial fibrosis overall or if this strain requires a higher dose
of cisplatin in order to develop fibrosis.
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Figure 1. Inflammatory markers in
C57BL/6J background mice and FVB/n
background mice. 8 wk old C57BL/6J and
FVB/n mice were injected (i.p.) with saline
vehicle or 7 mg/kg cisplatin once a week for
four weeks. Animals were sacrificed 72 h after
the last injection. Expression of (A) Tnf, (B)
Il6, (C) Cxcl1, (D) Mcp-1 was assessed in via
real-time qRT-PCR and were normalized to
B2M control. n=5-10; *indicates P<0.05, **
P<0.01, etc.

Figure 2. Fibrotic markers in C57BL/6J background
mice and FVB/n background mice. 8 wk old C57BL/6J
and FVB/n mice were injected (i.p.) with saline vehicle and 7
mg/kg cisplatin once a week for four weeks. Animals were
sacrificed 72 h after the last injection. Markers of pro-fibrotic
markers in the kidney cortex were assessed by real-time
qRT-PCR for (A) Pai-1 and (B) Col1a1. Levels of
myofibroblasts were determined by (C) α-SMA IHC. Total
collagen deposition was determined by (D) Sirius Red/Fast
Green Staining. n=5-10; *indicates P<0.05, ** P<0.01, etc.
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The Specific Aim was to determine if C57BL/6J mice require a higher dose of cisplatin
in order to develop interstitial fibrosis with repeated dosing of cisplatin. With this information,
the repeated dosing regimen model could be optimized to be used to model fibrosis in this strain
of mouse. Once a potential therapeutic target is found, it will be easier to purchase common
knock out or genetically manipulated mice to validate the therapeutic target.

Materials and Methods
*Materials and methods were repeated in the same manner as the work performed by Sharp, et. Al (5).

Reagents and antibodies. The following antibodies were purchased from Cell Signaling
(Beverly, MA) unless otherwise noted: cleaved caspase-3, fibronectin, and -actin.
Pharmaceutical grade cisplatin was purchased directly from the University of Louisville hospital
pharmacy.
Animals. FVB/n mice and C57Bl/6J mice were purchased from The Jackson Laboratory
(Bar Harbor, ME). All mice were maintained on a 12:12-h light-dark cycle and provided food
and water ad libitum. Animals were maintained under standard laboratory conditions. All animal
procedures were approved by the Institutional Animal Care and Use Committee of the University
of Louisville and followed the guidelines of the American Veterinary Medical Association. Mice
received either 7 or 9 mg/kg cisplatin administered by an intraperitoneal injection once a week
for 4 wk. Mice were monitored for weight loss and signs of discomfort/distress on a daily basis.
All mice survived the course of treatment and were euthanized 72 h after the fourth injection of
cisplatin. Serum was prepared and stored at -80C. The kidneys were flash frozen in liquid
nitrogen or fixed in 10% neutral buffered formalin.
Blood Urea Nitrogen (BUN) determination and Neutrophil Gelatinase Associated
Lipocalin (NGAL). BUN (DIUR-500) was determined using a kit from Bioassay Systems
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(Hayward, CA) following the manufacturer’s instructions. ELISA for NGAL (DY1857 R&D
Systems) was performed on the urine as directed by the manufacturer.
Protein Quantification. Homogenates were made from kidney cortex by homogenization
in Cell Extraction Buffer containing a Complete Protease Inhibitor Cocktail Tablet and
Phosphatase Inhibitor Cocktail Tablet. Homogenates were centrifuged at 15,000 X g for 10
minutes at 4°C. Supernatants were removed, vortexed, aliquoted, and stored at -80°C until use.
Protein concentrations were determined using BCA Assay (Bio-Rad, Hercules CA).
Western Blot Analysis. Kidney homogenate (40 μg) was separated on 4–12% gradient
tris-glycine-SDS polyacrylamide gels and transferred to PVDF membranes that were blocked in
5% (w/v) dried milk in tris-buffered saline containing 0.1% Tween-20 (TBST) for 15 minutes.
Membranes were incubated with 1:5000 dilutions of primary antibody overnight at 4°C. The
next morning, membranes were washed 3 times for 5 minutes each with TBST containing 5 %
(w/v) dried milk. After incubation for 1 hour at room temperature with secondary antibodies
conjugated with horseradish peroxidase (1:20,000 in TBST containing 1.25% (w/v) dried milk),
membrane proteins were detected by chemiluminiscence substrate.
Gene Expression. Total RNA was isolated using EZNA RNA Kit. cDNA was made from
1 μg of total RNA using High Capacity Reverse Transcriptase (Life Technologies, Grand Island
NY) following manufacturers’ instructions. Gene specific cDNAs were quantitated using realtime PCR with predesigned TaqMan

assays. Tumor necrosis factor-alpha (Tnf-α,

Mm00443258_m1), interleukin-6 (Il6; Mm00446190_m1), chemokine ligand (c-x-c motif) 1
(CXCL1; Mm04207460_m1), monocyte chemotactic protein-1 (MCP-1; Mm00441242_m1),
plasminogen activator inhibitor-1 (PAI-1; Mm00435860_m1), collagen type 1a1 (Col1a1;
Mm00801666_g1), and the normalization gene beta 2 microglobulin (B2M; Mm00437762_m1)
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were purchased from Life Technologies (Grand Island NY), and used in combination with iTaq
(Bio-Rad).
Immunohistochemistry. Kidney sections (5 microns thick) were rehydrated in Histoclear
followed by an ethanol gradient. Antigen retrieval was performed in citric acid buffer pH 6.0 at
95°C in a steamer for 30 min. Endogenous peroxidases were inhibited with 3% hydrogen
peroxide and dual endogenous enzyme blocker (Dako, S2003) for 10 minutes, followed by two 5
minute PBS washes. Slides were then blocked with avidin for 10 minutes followed by a PBS
wash, and then biotin for 10 minutes followed by another wash in PBS (Dako, X0590). Slides
were further blocked with 5% normal goat serum in 0.1% TBST for 1 hour at room temperature.
α-SMA primary rabbit antibody (Abcam, ab5694) was added to slides at a concentration of 0.5
μg/mL, and allowed to incubate at 4°C overnight. Biotinylated goat antirabbit IgG antibody
(1:25000) (Vector laboratories, BA-1000) was added to each section and incubated for 30
minutes at room temperature. Slides were rinsed twice with PBS for 5 minutes each. Vector
ABC reagent (Vector laboratories, PK-7100) was added to each section and incubated for 30
minutes at room temperature. Slides were rinsed 2 times with PBS for 5 minutes each, followed
by the addition of NovaRed Substrate to detect HRP (Vector Laboratories, SK-4800) to each
section for 5-7 minutes. Slides were rinsed in distilled water for 5 minutes, counterstained with
modified Mayer’s hematoxylin (Thermo-scientific, 72804), then dehydrated in an ethanol
gradient to Histoclear, followed by mounting with Permount (Fisher Scientific, SP15).
Sirius Red/ Fast Green Staining. Kidney sections (5 microns thick) were rehydrated in
Histoclear followed by an ethanol gradient. Slides were then dipped into a Coplin jar containing
PBS-T (PBS+0.1% tween-20) and incubated for 5 minutes. Slides were washed with distilled
water twice for 5 minutes each and then incubated in saturated picric acid (1.2% w/v, Ricca
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Chemicals; 5860-32) containing 0.1% Sirius Red (Sigma, 365548) and 0.1% Fast Green (Sigma,
F7258). Slides were washed with 5% glacial acetic water until water ran clear. Tissue samples
were then dehydrated and fixed using Permount (Fisher, F-SP15-100).
Statistical Analysis Data. Data are expressed as means ± SEM for all experiments.
Multiple comparisons of normally distributed data were analyzed by one-way ANOVA, as
appropriate, and group means were compared using Tukey post-tests. Single comparisons were
analyzed by Student’s t-test where appropriate. The criterion for statistical differences was p <
0.05*, p<0.01**, p<0.001***, and p<0.0001****. For statistical analysis of the survival curve,
Log-Rank (Mantel-Cox) test was used.

Results
Our established repeated dosing mouse model of cisplatin-induced kidney injury reflects
the dosing regimen that human patients receive. However, optimizing this model to be used in
multiple strains that have variations in susceptibility to some forms of renal fibrosis remains a
hurdle. Thus, we wanted to address this issue by determining optimal dose in the most common
used strain of mouse- C57BL/6J. As seen in the preliminary data, 7 mg/kg cisplatin was optimal
for FVB/n mice to develop fibrosis but not for C57BL/6J mice. To this end, five male C57BL/6J
mice were treated with vehicle saline once a week for four weeks and ten male C57BL/6J mice
(8 weeks old) were treated with 9 mg/kg of cisplatin once a week for four weeks. Both groups
were sacrificed three days after the last injection at Day 24. In order to compare the data
collected from the C57BL/6J mice, the same protocol was conducted with FVB/n mice with 9
mg/kg of cisplatin once a week for four weeks and sacrificed on Day 24. This was then
compared to the 7 mg/kg cisplatin for C57BL/6J and FVB/n mice as seen by Schematic 3.
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Figure 3. Kidney function and injury markers with repeated dosing model. 8 wk old C57BL/6J and
FVB/n mice were injected (i.p.) with saline vehicle and 7 mg/kg cisplatin once a week for four weeks.
Animals were sacrificed 72 h after the last injection. Levels of (A) Blood, urea, nitrogen (BUN) as a
measure of kidney function, and (B) Neutrophil gelatinase associated lipocalin (NGAL), a kidney injury
marker measured in urine. n=5-10; *indicates P<0.05, ** P<0.01, etc.

Markers of kidney function and injury in the serum and urine of FVB/n and
C57BL/6J mice. Blood urea nitrogen (BUN) is a measure of kidney function, in which its levels
increase in the blood when the filtering capacity of the kidney is significantly reduced. BUN
levels were not significantly increased at 7 or 9 mg/kg in either strain of mouse, suggesting little
decline in kidney function. However, BUN is a relatively insensitive marker of kidney injury.
Thus, we measured NGAL. Neutrophil gelatinase associated lipocalin (NGAL) is a measure of
kidney injury and is a sensitive biomarker of AKI. In C57BL/6J mice, NGAL levels increased
with 7 mg/kg and to the same level with 9 mg/kg. However, while FVB/n mice had slightly
lower NGAL at 7 mg/kg compared to C57BL/6J, at 9 mg/kg NGAL was greater.
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Figure 4: Inflammatory markers in C57BL/6J and FVB/n mice. 8
wk old C57BL/6J and FVB/n mice were injected (i.p.) with saline
vehicle and 7 mg/kg cisplatin once a week for four weeks. Animals were
sacrificed 72 h after the last injection. Expression of (A) Tnf, (B) IL6,
(C) Mcp-1, (D) Cxcl1 was assessed in via real-time qRT-PCR and were
normalized to B2M control. n=5-10; *indicates P<0.05, ** P<0.01, etc.
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Inflammatory cytokines and chemokines in FVB/n and C57BL/6J mice. Both strains
of mice treated with repeated dosing of cisplatin had a robust inflammatory response. As
previously mentioned, (A) Tnfα is a mediator of inflammatory tissue damage, (B) Il6 promotes
maintenance of a chronic inflammatory state, (C) Cxcl1 recruits neutrophils to sites of tissue
inflammation, and (D) Mcp-1 plays a role in macrophage recruitment and activation.
Tnfα levels (A) increased approximately 15-fold after 7 mg/kg repeated dosing in
C57BL/6J mice. Levels further increased with 9 mg/kg. Overall, Tnfα levels in FVB/n mice
treated with CDDP were lower compared to those seen in C57BL/6J mice. Tnfα increased 5-fold
at 7 mg/kg and was only 7-fold elevated with 9 mg/kg in FVB/n mice. The same trend was seen
for Il6 and Cxcl1 levels. Il6 levels (B) increased approximately 3-fold after 7 mg/kg repeated
dosing in C57BL/6J mice and further increased with 9 mg/kg. Il6 increased 5-fold at 7 mg/kg
and was only 6-fold elevated wtih 9 mg/kg in FVB/n mice. Furthermore, Cxcl1 (C) levels
increased 15-fold at 7 mg/kg and was further increased at 40-fold at 9 mg/kg in C57Bl/6J mice.
There was a 32-fold increase at 7 mg/kg but only a 18-fold increase at 9 mg/kg for FVB/n mice.
Mcp-1 levels (D) displayed further increased levels at 7 mg/kg compared to 9 mg/kg in C57Bl/6J
mice. Mcp-1 levels increased approximately 6-fold after 7 mg/kg repeated dosing in C57BL/6J
mice but was only 3-fold elevated with 9 mg/kg. Mcp-1 increased 5-fold with 7 mg/kg and was
6-fold elevated with 9 mg/kg in FVB/n mice.
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Figure 5: Fibrotic markers in C57BL/6J and FVB/n mice. 8 wk old C57BL/6J and FVB/n mice were
injected (i.p.) with saline vehicle and 7 mg/kg cisplatin once a week for four weeks. Animals were sacrificed
72 h after the last injection. Markers of pro-fibrotic markers in the kidney cortex were assessed by real-time
qRT-PCR for (A) Pai-1 and (B) Col1a1. Markers of fibrosis were assessed by Western Blot for (A)
Fibronectin and β-actin for the control. Levels of myofibroblasts were determined by (C) α-SMA IHC. Total
collagen deposition was determined by (D) Sirius Red/Fast Green Staining. Markers of apoptosis were
assessed by Western Blot for (F) Cleaved Caspase 3. n=5-10; *indicates P<0.05, ** P<0.01, etc.
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Fibrotic Markers in C57BL/6J and FVB/n mice. To

determine

the

presence

of

fibrosis, several markers were used. Pai-1, a pro-fibrotic marker, levels (A) increased
approximately 2-fold after 7 mg/kg repeated dosing in both C57BL/6J and FVB/n mice. Pai-1
levels in C57BL/6J mice were higher after 9 mg/kg repeated dosing compared to 9 mg/kg for
FVB/n mice. The same trend was seen for Col1a1 (B). Levels of fibronectin (C) increased at
both 7 mg/kg and 9 mg/kg in C57BL/6J mice. The same trend followed for FVB/n mice with
increased levels of fibronectin at both 7 mg/kg and 9 mg/kg.
α-SMA IHC (D) is a stain for myofibroblasts which produce extracellular matrix and are
expressed to repair and restore homeostasis after injury. In the C57BL/6J mice, there is a lack of
change in colors between the vehicle and 7 mg/kg cisplatin kidney sections but a distinct change
in color between the vehicle and 9 mg/kg cisplatin treated kidney section. Conversely, in the
FVB/n mice, there is a distinct color change between the vehicle and 7mg/kg cisplatin treated
kidney section. However, there is not a distinct change in color between the vehicle and 9 mg/kg
cisplatin treated kidney section. α-SMA staining occurs only at 9 mg/kg in C57BL/6J mice but at
7 mg/kg in FVB/n mice. These trends are consistent with the Sirius Red/Fast Green stain (E),
which is a stain for collagen deposition that results from extracellular matrix production.
Together, these results suggest that C57BL/6J mice develop fibrosis when treated with 9
mg/kg of cisplatin. As seen in the preliminary data, 7 mg/kg of cisplatin is not a high enough
dose of cisplatin in order to induce interstitial fibrosis indicative of that which a human patient
develops. However, 7 mg/kg of cisplatin is the optimal dose for FVB/n mice. When treated with
9 mg/kg of cisplatin, FVB/n mice do not develop as severe of fibrosis as the mice treated with 7
mg/kg of cisplatin but instead show high levels of Cleaved Caspase-3 (CC3), indicating cell
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death and perhaps a more severe form of injury. This is further confirmed by the presence of
CC3 in FVB/n mice treated with 9 mg/kg for western blot analysis (F).

Discussion
Clinically, patients receive cisplatin in low doses over an extended period of time to
maintain therapeutic efficacy while curtailing nephrotoxic side effects. Our repeated dosing
model better recapitulates the human dosing regimen, and with this study, we have shown that it
can be repeated in both FVB/n and C57BL/6J strains of mice. With repeated dosing, fibrosis
indicative of CKD develops. Patients with AKI are 10x more likely to develop CKD, and in
addition, other studies have shown that even patients who do not have clinical signs of AKI
develop poor long-term outcomes. Studies have been conducted to determine the extent of
genetic susceptibility as a risk factor for many diseases, in particular fibrosis (8). As previously
displayed in Table 2, different mouse strains have varying susceptibility to developing fibrosis
with the same organ. FVB/n mice have previously been shown to be susceptible to renal fibrosis,
specifically interstitial fibrosis, whereas C57BL/6J are not, according to Walkin’s studies (8).
However, our results show that C57BL/6J mice can develop fibrosis when administered a higher
dose of cisplatin. At this higher dose of 9 mg/kg, inflammatory cytokines and chemokine levels
increased (Tnfα, Il6, Cxcl1, and Mcp-1) as well as the pro-fibrotic markers Pai-1, Col1a1,
Fibronectin. α-SMA and Sirius Red/Fast Green staining further indicated fibrosis in FVB/n and
C57BL/6J mice. By studying different strains of mice, we may be better able to understand
whether genetic susceptibility plays a role in fibrogenesis.
Human patients may be susceptible to developing kidney injury and eventually chronic
kidney disease due to genetic factors. According to Varrier, the risk for developing AKI is
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determined by patient factors and nephrotoxic exposures (11). These patient factors include
hypericaemia, obesity, hypoalbuminaemia and certain genetic polymorphisms (11). AKI can also
lead to end-stage renal diseases such as chronic kidney disease (CKD), with risk factors such as
race, gender, age, and family history, and in particular for factors for developing CKD include
being of African-American decent, older age, low birth weight, and family history of kidney
disease (12). Determining whether fibrosis develops between two genetically different mice
strains can lead to insight and eventually novel treatments for fibrosis and kidney injury in
human patients.
With our repeated dosing model at 7 mg/kg in C57BL/6J mice, we saw that this dose was
too low to develop interstitial fibrosis. However, we have now optimized this model in
C57BL/6J mice with 9 mg/kg cisplatin so that they develop fibrosis. C57BL/6J mice are the most
commonly used strain of mouse in kidney research and the majority of the commercially
available genetically manipulated mouse models are on the C57BL/6J background. By doing so,
we can now use commonly available transgenic mice to identify and test novel therapeutic
targets with the more clinically relevant mouse model of cisplatin induced kidney injury.
Furthermore, this information can be translated to the differential effects of cisplatin in humans
and susceptibility to drug toxicities in order to determine a patient’s optimal administration and
dosage.
One future direction could be to specifically study the chemokine Cxcl1. As seen in
Figure 4, Cxcl1 follows the same pattern of increasing levels that we see with the development of
fibrosis, in which levels only increase at 7 mg/kg in FVB/n mice and only increase at 9 mg/kg in
C57BL/6J mice. Cxcl1 is a chemoattractant protein for neutrophils, indicating that neutrophils
may be necessary for the development of injury and subsequent fibrosis. A study could then be
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conducted using knockout mice for Cxcl1 to then see if the mice develop fibrosis.
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